- Home
- FSBC vs GYRE Comparison
FSBC vs GYRE Comparison
Compare FSBC & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FSBC | GYRE |
|---|---|---|
| Founded | 2002 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 821.1M | 759.1M |
| IPO Year | 2021 | 2004 |
Fundamental Metrics
Financial Performance| Metric | FSBC | GYRE |
|---|---|---|
| Price | $37.72 | $8.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $40.75 | $17.00 |
| AVG Volume (30 Days) | 53.4K | ★ 88.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.65% | N/A |
| EPS Growth | 28.32 | ★ 103.55 |
| EPS | ★ 2.90 | 0.04 |
| Revenue | N/A | ★ $275,000.00 |
| Revenue This Year | $29.27 | $11.59 |
| Revenue Next Year | $12.35 | $26.31 |
| P/E Ratio | ★ $13.01 | $193.78 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.22 | $6.11 |
| 52 Week High | $42.26 | $12.62 |
Technical Indicators
Market Signals| Indicator | FSBC | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 50.63 |
| Support Level | $36.20 | $7.10 |
| Resistance Level | $38.25 | $8.25 |
| Average True Range (ATR) | 1.51 | 0.58 |
| MACD | -0.38 | -0.06 |
| Stochastic Oscillator | 27.82 | 35.67 |
Price Performance
Historical ComparisonAbout FSBC Five Star Bancorp
Five Star Bancorp is a bank holding company through its subsidiary it operates in California state-chartered non-member bank. The Company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment; Banking.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.